CA-ODASEVA
27.2.2020 20:26:08 CET | Business Wire | Press release
Odaseva , the unified cloud data protection, compliance and operations platform for enterprises running Salesforce as a business-critical application, today announced that three people within company leadership have achieved the pinnacle of Salesforce certification known as the Salesforce Certified Technical Architect (CTA), including its CEO and Founder, Sovan Bin, who was one of the first individuals ever to reach Salesforce CTA status. Additionally, two other individuals at the company have achieved both the System Architect and the Application Architect credentials that are the qualifications needed to be able to even take for the CTA exam.
Due to the stringency of achieving this CTA certification, there are only 300-plus of these top Salesforce architects in the world.
Odaseva has been heavily investing in Salesforce architects as its management believes this level of expertise is a critical component in ensuring enterprise-level customer and partner success. The individuals at Odaseva who possess the CTA credential besides Sovan Bin are Master Architect Carl Brundage, and VP of Services, Marie Tourne.
Becoming a CTA is a long and challenging journey that requires five to eight years of experience with the Salesforce platform. Additionally, it requires candidates to stand in front of a panel of CTAs and prove their knowledge and skills in using Salesforce to solve complex business problems and transform the way organizations work.
“Obtaining CTA credentials serves as a membership into one of the most elite, sought-after groups of system architects in the world,” says Izak Mutlu, current Odaseva board member and the former Vice President of Information and Product Security at Salesforce.com. “By empowering its personnel to achieve such a status, Odaseva has truly distinguished itself among its competitors by offering the highest-level software architects in the world to tackle and eliminate the risks of enterprise performance issues and data loss.”
More organizations are turning to cloud platforms such as Salesforce to solve their most pressing business issues, and as such, Odaseva delivers enterprise-class data governance to its customers. The Odaseva platform provides data protection (backup and recovery as well as archiving and ultra high availability) and helps automate the most critical aspects of data privacy and compliance to meet the needs of such stringent laws such as GDPR and CCPA.
“As organizations become increasingly reliant on Salesforce, Odaseva will continue its mission to ensure customer data protection and compliance to empower business growth while meeting the constantly-evolving data privacy compliance requirements,” added Sovan Bin. “Our dedication to our customers and partners is unrivaled, and emphasizing reaching the highest level of certification for several of our people is one way to deliver above-and-beyond every day.”
For more information on Odaseva’s data governance platform and the CTA certification, visit www.odaseva.com .
About Odaseva
For enterprises that leverage Salesforce as a mission-critical application, Odaseva delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring and ultra high availability), data compliance for regulatory requirements such as GDPR and data operations (Salesforce DX data extensions). Odaseva was engineered for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures. Over 10 million Salesforce Enterprise users from industry-leading companies such as Schneider Electric, Heineken and Robert Half trust Odaseva’s data governance platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005893/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom